IL308389A - Dosing regimens for acubactadine - Google Patents
Dosing regimens for acubactadineInfo
- Publication number
- IL308389A IL308389A IL308389A IL30838923A IL308389A IL 308389 A IL308389 A IL 308389A IL 308389 A IL308389 A IL 308389A IL 30838923 A IL30838923 A IL 30838923A IL 308389 A IL308389 A IL 308389A
- Authority
- IL
- Israel
- Prior art keywords
- ecubectedin
- dosage regimens
- regimens
- dosage
- Prior art date
Links
- PVXBRBBFWHHDFS-DJQPDYNTSA-N [(1R,2R,3R,3'S,11S,12S,14R,26R)-5,12-dihydroxy-3'-(hydroxymethyl)-6-methoxy-7,21,30-trimethyl-27-oxospiro[17,19,28-trioxa-24-thia-13,30-diazaheptacyclo[12.9.6.13,11.02,13.04,9.015,23.016,20]triaconta-4(9),5,7,15,20,22-hexaene-26,1'-2,3,4,9-tetrahydropyrido[3,4-b]indole]-22-yl] acetate Chemical compound CC1=CC2=C([C@@H]3[C@@H]4[C@H]5C6=C(C(=C7C(=C6[C@@H](N4[C@H]([C@H](C2)N3C)O)COC(=O)[C@@]8(CS5)C9=C(C[C@H](N8)CO)C2=CC=CC=C2N9)OCO7)C)OC(=O)C)C(=C1OC)O PVXBRBBFWHHDFS-DJQPDYNTSA-N 0.000 title 1
- 229940125018 ecubectedin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382455 | 2021-05-19 | ||
| PCT/EP2022/063653 WO2022243482A1 (en) | 2021-05-19 | 2022-05-19 | Dosage regimens for ecubectedin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308389A true IL308389A (en) | 2024-01-01 |
Family
ID=76197383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308389A IL308389A (en) | 2021-05-19 | 2022-05-19 | Dosing regimens for acubactadine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240277705A1 (https=) |
| EP (1) | EP4340841A1 (https=) |
| JP (1) | JP2024521122A (https=) |
| KR (1) | KR20240009437A (https=) |
| CN (1) | CN117295499A (https=) |
| AU (1) | AU2022277799A1 (https=) |
| CA (1) | CA3218171A1 (https=) |
| IL (1) | IL308389A (https=) |
| MX (1) | MX2023013715A (https=) |
| TW (1) | TW202313039A (https=) |
| WO (1) | WO2022243482A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4563149A1 (en) * | 2023-11-30 | 2025-06-04 | Pharma Mar, S.A. | Lurbinectedin, ecubectedin and a related compound for use in the treatment of skin cancers |
| WO2025168075A1 (zh) * | 2024-02-08 | 2025-08-14 | 映恩生物科技(上海)有限公司 | 海鞘素类化合物及其应用 |
| TW202547489A (zh) | 2024-04-30 | 2025-12-16 | 西班牙商瑪製藥股份有限公司 | 化合物ia於包括與阿替利珠單抗的組合療法之癌症的治療中之用途 |
| WO2025228596A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Combination of pm14 and a topoisomerase i inhibitor in the treatment of cancer |
| WO2025228594A1 (en) | 2024-04-30 | 2025-11-06 | Pharma Mar, S.A. | Use of ecubectedin in the treatment of cancers including combination therapy with atezolizumab |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE368461T1 (de) * | 2004-10-29 | 2007-08-15 | Pharma Mar Sa | Zusammensetzungen enthaltend ecteinascidin und einen disaccharide |
| KR102491180B1 (ko) | 2017-04-27 | 2023-01-20 | 파르마 마르 에스.에이. | 항종양 화합물 |
| TWI824043B (zh) * | 2018-10-25 | 2023-12-01 | 西班牙商瑪製藥股份有限公司 | 藥物抗體共軛物 |
-
2022
- 2022-05-19 IL IL308389A patent/IL308389A/en unknown
- 2022-05-19 KR KR1020237042065A patent/KR20240009437A/ko active Pending
- 2022-05-19 EP EP22731103.2A patent/EP4340841A1/en active Pending
- 2022-05-19 MX MX2023013715A patent/MX2023013715A/es unknown
- 2022-05-19 AU AU2022277799A patent/AU2022277799A1/en active Pending
- 2022-05-19 JP JP2023572000A patent/JP2024521122A/ja active Pending
- 2022-05-19 WO PCT/EP2022/063653 patent/WO2022243482A1/en not_active Ceased
- 2022-05-19 TW TW111118548A patent/TW202313039A/zh unknown
- 2022-05-19 CN CN202280034530.0A patent/CN117295499A/zh active Pending
- 2022-05-19 CA CA3218171A patent/CA3218171A1/en active Pending
- 2022-05-19 US US18/560,991 patent/US20240277705A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024521122A (ja) | 2024-05-28 |
| US20240277705A1 (en) | 2024-08-22 |
| CA3218171A1 (en) | 2022-11-24 |
| CN117295499A (zh) | 2023-12-26 |
| EP4340841A1 (en) | 2024-03-27 |
| WO2022243482A1 (en) | 2022-11-24 |
| MX2023013715A (es) | 2024-03-26 |
| KR20240009437A (ko) | 2024-01-22 |
| AU2022277799A1 (en) | 2023-12-21 |
| TW202313039A (zh) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL308389A (en) | Dosing regimens for acubactadine | |
| IL287004A (en) | Dosage forms and regimens for amino acid compounds | |
| IL289949A (en) | Dosing regimens for oral complement factor d inhibitors | |
| IL291453A (en) | Dosage forms for tyk2 inhibitors | |
| IL287132A (en) | Abuse-resistant dosage forms that include asketamine | |
| GB202020191D0 (en) | Pharmaceutical compounds | |
| GB202010409D0 (en) | Pharmaceutical compounds | |
| ZA201802816B (en) | Melflufen dosage regimens for cancer | |
| IL281968A (en) | Dosage regimen for TFPI antagonists | |
| GB202010408D0 (en) | Pharmaceutical compounds | |
| GB202111193D0 (en) | Pharmaceutical compounds | |
| IL279214A (en) | Therapeutic dosage regimens comprising adherent stromal cells | |
| GB202104097D0 (en) | Pharmaceutical compounds | |
| IL315178A (en) | Dosage regimen | |
| IL308095A (en) | Dosing regimens | |
| GB202006819D0 (en) | Dosage regimen | |
| HK40108270A (zh) | 依维替定的给药方案 | |
| GB202102602D0 (en) | Pharmaceutical compounds | |
| GB202015771D0 (en) | Dosage regimen | |
| GB202014116D0 (en) | Dosage regimen | |
| GB202006699D0 (en) | Dosage regimen | |
| GB202319534D0 (en) | Dosage regimen | |
| GB202306662D0 (en) | Dosage regimen | |
| HK40105571A (zh) | Parp7抑制剂的剂量方案 | |
| GB201902454D0 (en) | Dosage regimen |